Quality Control

New HLA quality control

Actively waiting kidney patients with conflict between serological and genomic registered HLA type

December 3, 2012 a new HLA quality control was introduced. This new quality check is meant to disclose discrepancies between serological and genomic HLA types registered in the Scandiatransplant database.

The new quality control has been implemented and is accessible in two areas
1. For all kidney patients active on the waiting list
2. The STAMP quality check

1. For all kidney patients active on the waiting list

How to find the new quality control:
Main menu → Quality control → Actively waiting patients with conflicting sero/geno HLA

For instance if a tissue type has been entered serological as A3 and genomic as A*32 it will appear in the quality control like this:

<table>
<thead>
<tr>
<th>Cnt Scandia</th>
<th>Name</th>
<th>WI</th>
<th>WI. entry</th>
<th>Conflicting HLA</th>
</tr>
</thead>
<tbody>
<tr>
<td>AR 1234</td>
<td>Test</td>
<td>KI</td>
<td>04-DEC-2012</td>
<td>Geno A32 Sero A3</td>
</tr>
</tbody>
</table>
Please notice that DR5 and DR6 was at a time used for match, but they are now considered as obsolete and instead DR11, 12, 13 and 14 are used for match. (DR11 and DR12 was originally splits of DR5 – DR13 and DR14 of DR6)

Looking at the example above the recipient has been registered serological as DR4, 5 and genomic as DRB1*04, *11. As DR11 was once consider to be a split of DR5, the registered tissue typing result is not wrong, however as DR5 is no longer used for match in the database it pops up as an invalid result.

In these cases you can do one of two things:
Conclude that there is basically nothing wrong with the registered HLA typing result and as the genomic type overrules the serological you leave it as it is or update/delete the 'old' serological DR5/DR6 to remove it from the list in the quality control.

2. The STAMP quality check
As described in newsletter 'September-2011' it is at any time in the STAMP process possible to check if all STAMP acceptance criteria, as described in the STAMP guidelines, are fulfilled. (http://www.scandiatransplant.org/news/SCTP%20News%20September%202011.pdf)
To the list of STAMP quality checks, consistency between serological and genomic HLA has been added. The result are included in the STAMP recipient report and in the email sent to the STAMP steering committee.